Search Results

0 results for 'Fresenius'

You can use to get even better search results
July 25, 2024 | New Jersey Law Journal

Gibbons on the Case: New Jersey Firm Launches 15 Suits for Drug Company

The suits stem from defendants' submission to the U.S. Food and Drug Administration of Abbreviated New Drug Applications [ANDA] seeking permission to manufacture generic versions of American Regent's selenious acid products before their patents expire.
2 minute read
May 30, 2024 | New Jersey Law Journal

Lawsuits Are Flying Over Generic-Drug Disputes: Surge in Patent Litigation

Five of the suits were filed by Esperion Therapeutics, which seeks to stop competitors from selling generic versions of the company's cholesterol drug Nexletol.
4 minute read
May 28, 2024 | The Legal Intelligencer

'No Better Than a Racket'—Seventh Circuit Critical of Mootness Fees for Merger Disclosures

Judge Frank Easterbrook, disenchanted with the current "federal practice" of plaintiffs attorneys extorting fees in disclosure cases without conferring a meaningful benefit on stockholders, penned the opinion for a two-judge panel rejecting such fee agreements and empowering shareholders and federal courts alike to scrutinize these fees going forward.
6 minute read
May 15, 2024 | Law.com

Record $41M Jury Verdict Awarded to Lawyer for Medical Malpractice Claims

"The jury's verdict is bittersweet for this wonderful family, which has been devastated by Craig Pierce's injury and the loss of his ability to function independently and practice law," Christopher Hurley, a founding partner at Hurley McKenna & Mertz, said in a statement.
5 minute read
January 19, 2024 | New Jersey Law Journal

Big Law Squares Off in Battle Over Prescription Drug Prices

Courts have consistently rejected challenges under the Takings Clause to federal health care programs that seek to limit costs, according to an amicus curiae brief by a panel of nine nationally recognized experts in Medicare and medical finance.
5 minute read
November 20, 2023 | New Jersey Law Journal

Genentech, Biogen and Hoffmann-La Roche File Lawsuit Over Planned Release of 'Copycat' of Pioneering Cancer Drug

This complaint was first surfaced by Law.com Radar.
3 minute read
December 06, 2022 | Daily Business Review

Blue Chips Front Money for Buyers of Their Unwanted Assets

Dealmakers are dusting off their playbooks from the global financial crisis, devising creative ways to get transactions completed as traditional financing sources dry up.
3 minute read
October 14, 2022 | New York Law Journal

The Three Big Words at the Center of the Twitter Saga

Instances of a Delaware Court finding that a "material adverse effect" has occurred are few and far between, so a ruling that one has occurred in this case would have been atypical.
10 minute read
September 28, 2022 | The Legal Intelligencer

Patents: Discretionary Denials and the Consequences of Gameplaying

This article is directed to such discretionary denials, and the difficulties arising from the lack of denial standards and from the gamesmanship of counsel, and the pending movement toward rulemaking to alleviate these concerns.
8 minute read
September 02, 2022 | Law.com

Skilled in the Art With Scott Graham: Don't Say 'Invalid.' Apple Faces Gag in $576M Patent Appeal + If an RFID Patent Goes Down, Will a $20M Discovery Sanction Go With It?

WilmerHale, MoloLamken and Paul Hastings will square off at the Federal Circuit next week over a $576 million patent infringement judgment. The USPTO has ruled the patents invalid, but that might not do Apple any good.
8 minute read

Resources

  • 2024 Trends Report Mid-Year Special Edition: Update on Outside Counsel Billing Rates

    Brought to you by LexisNexis® CounselLink®

    Download Now

  • AI in Private Equity: A Guide for Gaining an Early Advantage

    Brought to you by Ontra

    Download Now

  • Why Are So Many Law Firms Suddenly Embracing Digital Transformation?

    Brought to you by AllRize

    Download Now

  • 2025 State Legislative Sessions

    Brought to you by LexisNexis®

    Download Now